ArticleJournal of medicinal chemistry2022
Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Differential regulation of SIRT5 activity by reduced nicotinic acid riboside (NARH).RSC chemical biology · 2026Article
- Targeting MFF succinylation: a novel therapeutic strategy for premature ovarian insufficiency by restoring mitochondrial dynamics in granulosa cells.Journal of ovarian research · 2026Review
- A Combined SIRT5 Activation and SIRT3 Inhibition Prevents Breast Cancer Spheroids Growth by Reducing HIF-1α and Mitophagy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Benzodeazaoxaflavin Sirtuin Inhibitors InhibitACS infectious diseases · 2025Article
- Unraveling Small Molecule-Mediated Sirtuin 3 Activation at a Distinct Binding Site for Cardioprotective Therapies.ACS central science · 2025Article
- Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Activation and inhibition of sirtuins: From bench to bedside.Medicinal research reviews · 2025Review
- Cardioprotection Through Pharmacological Activation of Sirtuin 5 in a Murine Model of Acute Myocardial Infarction.Drug design, development and therapy · 2025Article
- The Role of Mitochondrial Sirtuins (SIRT3, SIRT4 and SIRT5) in Renal Cell Metabolism: Implication for Kidney Diseases.International journal of molecular sciences · 2024Review
- Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions.Biomolecules · 2024Review
- Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases.Trends in pharmacological sciences · 2024Review
- Current Trends in Sirtuin Activator and Inhibitor Development.Molecules (Basel, Switzerland) · 2024Review
- SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process.Journal of medicinal chemistry · 2024Review
- Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.Theranostics · 2024Review
- The role of neurovascular coupling dysfunction in cognitive decline of diabetes patients.Frontiers in neuroscience · 2024Review
- Mitochondrial Sirtuins in Cancer: A Revisited Review from Molecular Mechanisms to Therapeutic Strategies.Theranostics · 2024Review
- SIRT5 Activation and Inorganic Phosphate Binding Reduce Cancer Cell Vitality by Modulating Autophagy/Mitophagy and ROS.Antioxidants (Basel, Switzerland) · 2023Article
- Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity and Downregulate Hypoxia-Induced Targets in Cancer Cells.Journal of medicinal chemistry · 2023Article
- Multichannel Recovery Potential with Activated Autologous Intraovarian Platelet-Rich Plasma and Its Derivatives.Medicines (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 4 countries.
Benjamin SuenkelDepartment of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany.
Sergio ValenteDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.ORCID 0000-0002-2241-607X
Clemens ZwergelDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.ORCID 0000-0002-3097-0003
Sandra WeissDepartment of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany.
Elisabetta Di BelloDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.
Rossella FioravantiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.
Michele AventaggiatoDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
João A AmorimDepartment of Life Sciences, University of Coimbra, 3004-504 Coimbra, Portugal.
Neha GargGenetics Department, Blavatnik Institute, Glenn Center for Biology of Aging Research, Harvard Medical School, Boston, Massachusetts 02115, United States.
Surinder KumarDepartment of Pathology, University of Michigan, Ann Arbor, Michigan 48109-2800, United States.
David B LombardDepartment of Pathology, University of Michigan, Ann Arbor, Michigan 48109-2800, United States.
Tuo HuThe Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198-7696, United States.
Pankaj K SinghThe Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198-7696, United States.
Marco TafaniDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Carlos M PalmeiraDepartment of Life Sciences, University of Coimbra, 3004-504 Coimbra, Portugal.
David SinclairGenetics Department, Blavatnik Institute, Glenn Center for Biology of Aging Research, Harvard Medical School, Boston, Massachusetts 02115, United States.
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.ORCID 0000-0001-9176-2382
Clemens SteegbornDepartment of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany.ORCID 0000-0002-0913-1467
Istituto Pasteur · ITHarvard University · USUniversity of Bayreuth · DESapienza University of Rome · ITUniversity of Michigan · USUniversity of Nebraska Medical Center · USUniversity of Coimbra · PT
Funding
Targeting Tumor-Stromal Metabolic Cross-Talk in Pancreatic CancerR01CA163649 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Pankaj Kumar Singh · 2012 to 2026
$5.4MRegulation of one carbon metabolism and epigenetics by SIRT5R01GM101171 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2012 to 2021
$2.6MMetabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic CancerR01CA216853 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SINGH, PANKAJ KUMAR · 2017 to 2021
$2.6MTargeting the Metabolic Basis of Cachexia in Pancreatic CancerR01CA210439 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SINGH, PANKAJ KUMAR · 2017 to 2021
$2.6MElucidating mechanisms of SIRT1 activationR01DK100263 · NIDDK · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2016 to 2020
$2.5MElucidating epigenetic mechanisms of cellular cadmium toxicityR21ES032305 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2020 to 2021
$427kNCI NIH HHS R01 CA163649NCI NIH HHS R01 CA210439NCI NIH HHS R01 CA216853NIDDK NIH HHS R01 DK100263NIEHS NIH HHS R21 ES032305NIGMS NIH HHS R01 GM101171
Abstract
Sirtuins are NAD
Indexed as
Sirtuin 3SirtuinsHumansNADPeptidesProtein IsoformsSirtuin 1NADPeptidesProtein IsoformsSIRT3 protein, humanSIRT5 protein, humanSirtuin 1Sirtuin 3Sirtuins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.